ViaCyte, Inc., a leader in the emerging field of regenerative medicine, headquartered in San Diego, California, is developing a novel combination product for patients with insulin-requiring diabetes. ViaCyte’s innovative VC-01™ product is based on the differentiation of stem cells into PEC-01™ pancreatic beta cell precursors, with subcutaneous implantation in the Encaptra® drug delivery system, a retrievable and immune-protective encapsulation medical device. Once implanted, the precursor cells mature into endocrine cells that secrete insulin and other hormones in a regulated manner to control blood glucose levels. ViaCyte’s goal is a product that can free patients with type 1 and type 2 diabetes from long-term insulin dependence. ViaCyte has received substantial financial support from both the California Institute for Regenerative Medicine (CIRM) and JDRF.